Nutra Pharma Corp (NPHC) Short term Debt (2010 - 2026)

Nutra Pharma has disclosed Short term Debt across 17 years of filings, most recently posting $110500.0 for Q1 2026.

• In Q1 2026, Short term Debt fell 98.76% year-over-year to $110500.0; the TTM figure through Mar 2026 stood at $110500.0 (down 98.76% YoY), while the FY2025 annual figure was $9.6 million, up 13.35% from the prior year.
• Short term Debt came in at $110500.0 for Q1 2026 at Nutra Pharma, down from $9.6 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $9.6 million in Q4 2025 to a low of $110500.0 in Q1 2026.
• Average Short term Debt over 5 years is $7.9 million, with a median of $8.3 million recorded in 2022.
• Year-over-year, Short term Debt grew 15.01% in 2025 and slumped 98.76% in 2026.
• Over 5 years, Short term Debt stood at $7.9 million in 2022, then increased by 4.97% to $8.3 million in 2023, then gained by 1.94% to $8.5 million in 2024, then gained by 13.35% to $9.6 million in 2025, then plunged by 98.85% to $110500.0 in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $110500.0 in Q1 2026, $9.6 million in Q4 2025, and $9.5 million in Q3 2025.